Home → E-shop → Antiviral compounds → Lamivudine triphosphate – CAS 143188-53-8

Lamivudine triphosphate – CAS 143188-53-8

Lamivudine triphosphate – CAS 143188-53-8 is synthesised by Sigut Labs (Prague, Czech Republic).

Purity (LC-MS)

99%+

Package contents

Lamivudine triphosphate Et₃NH⁺salt

This compound is for research use only. We do not sell to patients.

Amount

1 mg	€ 450	Stock
5 mg	€ 1900	Stock
10 mg	€ 3500	Stock
100mM/10μL	€ 450	Stock
10mM/100μL	€ 450	Stock
Do you want custom amount?			Custom amount

Amount

1 mg

€ 450

Stock

5 mg

€ 1900

Stock

View more amounts

Characterisation

CAS: 143188-53-8, 2736455-56-2 (Et3NH+ salt)

IUPAC name: Triphosphoric acid, P-[[(2R,5S)-5-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1,3-oxathiolan-2-yl]methyl] ester

Other names: Lamivudine triphosphate, Lamivudine TP

Molecular weight: 469.20 g/mol

Molecular formula: C₈H₁₄N₃O₁₂P₃S

InChI: InChI=1S/C8H14N3O12P3S/c9-5-1-2-11(8(12)10-5)6-4-27-7(21-6)3-20-25(16,17)23-26(18,19)22-24(13,14)15/h1-2,6-7H,3-4H2,(H,16,17)(H,18,19)(H2,9,10,12)(H2,13,14,15)/t6-,7+/m0/s1

Description

Lamivudine, commonly called 3TC, is an antiretroviral medication used to prevent and treat HIV/AIDS. It is also used to treat chronic hepatitis B when other options are not possible. It is effective against both HIV-1 and HIV-2. It is typically used in combination with other antiretrovirals such as zidovudine and abacavir. Lamivudine may be included as part of post-exposure prevention in those who have been potentially exposed to HIV. Lamivudine is taken by mouth as a liquid or tablet.

Common side effects include nausea, diarrhea, headaches, feeling tired, and cough. Serious side effects include liver disease, lactic acidosis, and worsening hepatitis B among those already infected. It is safe for people over three months of age and can be used during pregnancy. The medication can be taken with or without food. Lamivudine is a nucleoside reverse transcriptase inhibitor and works by blocking the HIV reverse transcriptase and hepatitis B virus polymerase.

Lamivudine was patented in 1995 and approved for use in the United States in 1995. It is on the World Health Organization’s List of Essential Medicines. It is available as a generic medication.

You can find more information about antiviral drug research at Sigut Labs in our article.

Chemicals are distributed worldwide

Buy Lamivudine triphosphate now, and get your order in 48 hours

Shipping through DHL in 48 hours
Sensitive compounds are shipped on dry ice
All compounds are safely and rigorously packed

Payment

Payment terms 30 days net
We are sending the invoice the same day as the shipment
We are able to modify the invoice for the academic institution, so the order can be paid from grants

References

Johnson, M. A., Moore, K. H., Yuen, G. J., Bye, A., & Pakes, G. E. (1999). Clinical pharmacokinetics of lamivudine. Clinical pharmacokinetics, 36, 41-66.
Lai, C. L., Chien, R. N., Leung, N. W., Chang, T. T., Guan, R., Tai, D. I., … & Gray, D. F. (1998). A one-year trial of lamivudine for chronic hepatitis B. New England Journal of Medicine, 339(2), 61-68.
Dienstag, J. L., Goldin, R. D., Heathcote, E. J., Hann, H. W. L., Woessner, M., Stephenson, S. L., … & Schiff, E. R. (2003). Histological outcome during long-term lamivudine therapy. Gastroenterology, 124(1), 105-117.
Perry, C. M., & Faulds, D. (1997). Lamivudine: a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection. Drugs, 53, 657-680.